Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03624660 · ClinicalTrials.gov registry record · Phase 2
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
A Phase 2 study of Adenocarcinoma of the Prostate, sponsored by University of Florida.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03624660 is a Phase 2 study of Adenocarcinoma of the Prostate that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 100 participants, roughly in line with the 105-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT03624660, a Phase 2 study of Adenocarcinoma of the Prostate, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine if dose-escalated proton radiation therapy is a good way to treat high-risk prostate cancer. The study features hypofractionation and a simultaneous integrated boost to the magnetic resonance imaging (MRI) identified intraprostatic tumor (IPT) as a method of dose-escalating radiation therapy. The study will include patients with high-risk prostate cancer who are at the highest risk for recurrence. Radiation therapy will be delivered over the course of 8-9 weeks. Additionally, androgen deprivation therapy (ADT) will be started 8-10 weeks prior to starting radiation and continued for a total of 18 months if the patient decides to receive ADT.
Conditions Studied
Interventions
- RADIATION HR-A
- RADIATION HR-B
Study Locations (1)
Florida
- University of Florida Health Proton Therapy Institute - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03624660
The ClinicalTrials.gov registry entry for NCT03624660 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 105-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adenocarcinoma of the Prostate appearing as the primary indexed condition, and to 2 interventions - of which HR-A is the first listed.
NCT03624660 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03624660 about?
NCT03624660 is a clinical study titled "Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer". The purpose of this research study is to determine if dose-escalated proton radiation therapy is a good way to treat high-risk prostate cancer. The study features hypofractionation and a simultaneous integrated boost to the magnetic resonance imaging (MRI) identified intraprostatic tumor (IPT) as a ...
What is the current status of trial NCT03624660?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2018-09-24. Estimated completion is 2028-09.
What conditions does trial NCT03624660 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Prostate.
What interventions are being tested in trial NCT03624660?
The interventions under investigation include: HR-A (RADIATION), HR-B (RADIATION).
Who is sponsoring clinical trial NCT03624660?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03624660 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
COMPLETED · Phase 2
-
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
COMPLETED · Phase 2
-
Enzalutamide in Patients With High-risk Prostate Cancer
COMPLETED · Phase 2
-
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
COMPLETED · Phase 2
-
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
COMPLETED · Phase 2
-
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.